Several studies have reported a reduced pulmonary diffusion capacity for carbon monoxide after total body irradiation (TBI) and/or high-dose chemotherapy (HDCT) and autologous peripheral blood progenitor transplantation (APBPC). The present study describes the oxygenation of arterial plasma (paO 2 ), the maximum exercise capacity (Wmax) and maximum oxygen transport (VO 2 max) before and after such treatment. Pulmonary gas exchange and paO 2 were measured in 15 patients at maximum dynamic bicycle exercise, performed before and at 8 ؎ 0.9 (s.e.m.) months after TBI/HDCT (n = 12) and HDCT (n = 3) followed by APBPC. Wmax was 169 ؎ 14 and 157 ؎ 15 watts (P Ͼ 0.05) before and after therapy, respectively. VO 2 max, 1.8 ؎ 0.1 l/min before treatment, fell to 1.6 ؎ 0.1 l/min (P Ͻ 0.05) after therapy. The maximum exercise paO 2 was 13.2 ؎ 0.4 kPa before and 13.6 ؎ 0.4 kPa (P Ͼ 0.05) after the treatment period. The findings indicate no significant reduction of Wmax or pulmonary diffusion capacity for O 2 after TBI/HDCT and APBPC while VO 2 max fell modestly by approximately 11%. The study was restricted to patients who remained in remission. Keywords: arterial plasma pO 2 ; hematological malignancies; hematopoietic stem cell transplantation; maximum oxygen uptake; pulmonary diffusion capacity Since the introduction of allogeneic bone marrow transplantation (BMT) for the treatment of hematological and other disorders, pulmonary toxicity has been of particular concern and has significantly contributed to both morbidity and mortality (10-40% of toxicity-related deaths).
Since the introduction of allogeneic bone marrow transplantation (BMT) for the treatment of hematological and other disorders, pulmonary toxicity has been of particular concern and has significantly contributed to both morbidity and mortality (10-40% of toxicity-related deaths). 1 Major factors, thought to be associated with pulmonary toxicity/dysfunction and delayed/incomplete recovery of pulmonary function tests in the allogeneic BMT setting are total body irradiation (TBI), acute and chronic graft-versushost disease and post-transplant pulmonary infection. 2, 3 The rapidly increasing number of patients undergoing high-dose treatment with autologous stem cell transplanCorrespondence: Dr T Brundin, Department of Clinical Physiology, Karolinska Hospital, SE-171 76 Stockholm, Sweden Received 6 November 1998; accepted 8 March 1999 tation may present an increasing medical problem with regard to cardiopulmonary sequelae. Procedure-related morbidity and mortality for patients with hematological and solid tumors have been substantially reduced by new developments in stem cell processing, eg autologous peripheral blood progenitor transplantation (APBPC) and improved supportive care. Nevertheless, cardiopulmonary complications have remained a major threat. 4 With the introduction of non-TBI containing high-dose therapies and the omission or dose-reduction of BCNU, acute and long-term lung toxicity seem to have decreased. [5] [6] [7] However, published studies reveal considerable variations concerning patient populations, types of high-dose treatment and stem cell sources, post-transplantation treatments, and methods used for the evaluation of cardiopulmonary function. Several earlier studies have indicated that chemotherapy and TBI prior to bone marrow transplantation may lead to pulmonary dysfunction, including a reduced diffusion capacity for carbon monoxide (CO) within the first months after the therapy period. 5, 8, 9 However, the functional consequences of these findings are incompletely studied and understood.
The present study was undertaken to find out to what extent chemotherapy and/or irradiation also affect real pulmonary diffusion capacity for O 2 , maximum O 2 transport capacity (VO 2 ) or maximum capacity for dynamic exercise (Wmax). From functional points of view an impaired diffusion capacity for O 2 might be of more direct biological interest than the impairment of that for CO. Therefore, patients were subjected to a maximum exercise test including measurements of VO 2 max and arterial plasma O 2 -tension (paO 2 ) at Wmax, before and after high-dose treatment. The analysis was restricted to patients who remained in remission and received no further treatment following chemotherapy in combination with TBI.
Materials and methods

Patients
Fifteen patients (F/M = 4/11) with hematological malignancies participated in the study. Median age at the time of APBPC was 52 years (range 30-62). Five patients had multiple myeloma (MM), four non-Hodgkin's lymphoma (NHL), three acute myelocytic leukemia (AML), two chronic myelocytic leukemia (CML), and one acute lymphocytic leukemia. Twelve patients received fractionated TBI: 3 Gy each day for 4 consecutive days, delivered by a linear accelerator with a dose rate of 0.14 Gy/min. Lung shielding was used for 10% of the dose. Seven patients were given TBI in combination with cyclophosphamide (80 mg/kg intravenously (i.v.) day Ϫ4), and etoposide (30 mg/kg i.v. days Ϫ6 and Ϫ5). 10 Three patients with MM also received melphalan (140 mg/m 2 i.v. day Ϫ5), 11 and two patients with AML received it in combination with cytarabine (1 g/m 2 twice a day i.v. days Ϫ6 to Ϫ1). 12 Two patients with CML were treated with busulfan (1 mg/kg four times daily orally days Ϫ6 to Ϫ3), etoposide (10 mg/kg i.v. days Ϫ6 to Ϫ4) and cyclophosphamide (60 mg/kg i.v. day Ϫ2) and one patient (NHL) received BEAM (BCNU) high-dose chemotherapy 13 
Methods
Before and at 8 Ϯ 0.9 months after high-dose treatment and APBPC, each patient was subjected to a graded maximum exercise test. Prior to the test, a thin catheter was inserted percutaneously under local anesthesia into a brachial artery. Exercise was performed sitting on an electrically braked bicycle ergometer. The work load, starting at 30-50 watts, was continuously increased by 10 watts/min. Patients were encouraged to perform their absolute maximum exercise and inform the investigator clearly on which symptom was the limiting factor. Respiratory exchange of O 2 and CO 2 was measured by means of continuous breath-by-breath analysis (MEDGRAPHICS, System CPX/D; Medical Graphics, St Paul, MN, USA) using a nose-clip and mouthpiece technique with which the patients had been made familiar. Arterial blood samples for blood gas analysis were drawn at rest before exercise, at maximum exercise, and at 3 min after exercise in the supine position. Blood plasma pO 2 , pCO 2 , and pH were analyzed using an automated blood gas analyzer (ABL 3; Radiometer, Copenhagen, Denmark). Numbers in the text, Tables and Figures are given as mean values Ϯ s.e.m. The Students paired t-test was used for calculations of significant differences. Table 1 , Figure 1 Before the treatment period, Wmax was 169 Ϯ 14 watts, well within normal ranges for gender, age, and body dimensions. After treatment it was 157 Ϯ 15 watts, not significantly lower than before (P Ͼ 0.05; Table 1) . Individual values are given in Figure 1 . The Wmax limiting symptoms were before/after the treatment period: leg muscle fatigue in 9/7 patients, breathlessness in 4/5 patients, general fatigue in 2/3 patients ( Table 2) . Table 1 Maximum exercise values for working capacity (Wmax), pulmonary O 2 -uptake (VO 2 pulm) in absolute terms and related to body weight and heart rate, pulmonary ventilation (VE-pulm), heart rate (HR), respiratory rate (RR), arterial plasma pO 2 Figure 2 Before the treatment period, VO 2 max was in absolute terms 1.8 Ϯ 0.1 l/min. After treatment it was 1.6 Ϯ 0.1 l/min, 11% lower (P Ͻ 0.02). Individual values are given in Figure 2 . VO 2 max/body weight was 24 Ϯ 2 ml/min/kg before and 22 Ϯ 2 ml/min/kg (P Ͻ 0.05) after treatment. VO 2 max/maximum exercise heart rate was 12 Ϯ 1 ml/heart beat before and 11 Ϯ 1 ml/heart beat (P Ͼ 0.05) after treatment. 
Results
Maximum exercise capacity (Wmax),
Pulmonary ventilation at maximum exercise
The pulmonary ventilation at maximum exercise was 43 Ϯ 3 and 45 Ϯ 1 l/min (P Ͼ 0.05) before and after treatment, respectively. The corresponding numbers for respiratory rate were 37 Ϯ 1 and 38 Ϯ 2 breaths/min (P Ͼ 0.05) ( Table 1) .
Heart rate
Maximum exercise heart rate was 162 Ϯ 3 beats/min before and 156 Ϯ 3 beats/min (P Ͼ 0.05) after treatment ( Table 1) .
Arterial plasma O 2 tension (paO 2 ), Table 1, Figure 3
At rest paO 2 was 11.3 Ϯ 0.4 and 12.1 Ϯ 0.5 kPa (P Ͼ 0.05) before and after the treatment period, respectively. At maximum exercise the corresponding values were 13.2 Ϯ 0.4 and 13.6 Ϯ 0.4 kPa (P Ͼ 0.05), and at 3 min after exercise 14.4 Ϯ 0.4 and 15.3 Ϯ 0.4 kPa (P Ͼ 0.05).
Individual maximum exercise values are given in Figure 3 .
Discussion
Earlier studies have clearly indicated a high incidence of impaired pulmonary diffusion capacity for CO after APBPC and BMT. 8, 9, 14 Reduction in diffusion capacity, measured under resting conditions by means of the highly sensitive CO method, was found to be most frequent and pronounced at 6 months after the treatment period but less so 18 months later. 9 These findings, however, do not necessarily indicate that lung diffusion capacity was reduced to an extent that impaired diffusion of oxygen.
The classical work by August and Marie Krogh 15, 16 showed conclusively that the only mechanism for oxygen transport from alveolar gas into the lung capillary is passive gas diffusion. This is a time-consuming process. Thus, in healthy individuals at rest, when blood flow rate through the lung capillaries is relatively low, the blood will be fully saturated with oxygen after passing approximately 1/3 of the total lung capillary length. However, during heavy exercise, when the blood flow rate is high, the blood will require passage of almost the entire lung capillary length to reach full oxygen saturation. Therefore a patient with a small to moderate reduction of lung diffusion capacity may exhibit a normal paO 2 at rest; during exercise, a normal or slightly reduced paO 2 . In consequence, a markedly reduced paO 2 during maximum exercise is obligatory in an air-breathing patient with clinically significant impairment of lung diffusion capacity.
To study the functional effects of TBI/HDCT and APBPC on lung diffusion capacity for oxygen, we employed the condition of maximum exercise which provokes the highest possible blood flow rate through the lung capillaries and thereby constitutes the most sensitive test on functional pulmonary diffusion capacity for O 2 . No previous studies of the effects of such treatment on Wmax or arterial plasma oxygenation at maximum exercise are known to us. In one study, 17 including submaximal exercise of relatively low intensity, performed 6 and 12 months after treatment, transcutaneous pO 2 was found to be lower after than before autologous BMT. However, no directly measured arterial plasma pO 2 values were reported.
Our most remarkable findings were that neither Wmax nor the oxygenation of arterial plasma at or just after maximum exercise was significantly impaired in the 15 patients studied before and at 8 months after HDCT/TBI. Neither were there any signs of increasing respiratory limitation of the maximum exercise capacity. The exercise limiting symptom, leg muscle fatigue, indicated that the degree of physical training constituted the limiting factor for maximum performance in most of the patients both before and after the treatment period. The finding of a 11% reduction of VO 2 max after the treatment period tallies well with a reduced degree of muscular physical training since the ratio between VO 2 max and maximum heart rate was unchanged.
Mainly depending on the type of high-dose treatment used, monitoring of cardiopulmonary function has revealed variable degrees of dysfunction at one to several years after HDCT/TBI. However, in the majority of patients this dysfunction has been limited and of no major clinical significance. 17, 18 The present findings indicate that HDCT/TBI followed by APBPC may be performed without significant functional impairment of the O 2 transport system. Thus, the frequently found reduced diffusion capacity for CO after such treatment may reflect a diffusion impairment of little functional or clinical significance.
